Can a new pill silence stubborn hives?

NCT ID NCT07766499

Not yet recruiting Disease control Sponsor: Calixis Inc. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing an experimental oral medication called THB335 in adults with chronic spontaneous urticaria (CSU), a condition marked by persistent hives and itching that standard antihistamines don't fully control. Participants will take THB335 or a placebo alongside their usual antihistamine for 12 weeks. The study aims to see if THB335 can reduce the severity and frequency of hives and itching, potentially offering a new treatment option for those who remain symptomatic.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: THB335, an oral capsule taken alongside a standard antihistamine
What this could lead to: If successful, THB335 could offer a new oral option for people with chronic hives that are not controlled by current treatments, potentially improving their quality of life.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may also have side effects or may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC IDIOPATHIC URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC IDIOPATHIC URTICARIA CHRONIC SPONTANEOUS URTICARIA (CSU)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.